Worcester Business Journal

wbjournal.com | April 1, 2024 | Worcester Business Journal 5 Natick pharma names COO as CEO AffyImmune erapeutics, a biopharmaceutical company headquartered in Natick, has promoted Chief Operating Officer Matt Britz to the role of CEO and named Pete Gelinas as its new senior vice president of chemistry, manufacturing, and controls. Britz, who joined AffyImmune as its senior vice president, business development in June 2021, has 28 years of life science-related experience. Britz is the first CEO in AffyImmune history. AffyImmune is working to develop CAR T cell therapies, which utilizes patients' own immune systems to target and destroy cancer cells. e company has 11 local employees and 24 employees company- wide, according to data the company submitted to WBJ. Britz previously served as senior vice president and head of business development at Minerva Biotechnologies, a Waltham-based biotechnology company. He holds a MBA and a master's degree in biology from Washington University in St. Louis and a bachelor's degree in chemical engineering and biology from the Massachusetts Institute of Technology in Cambridge. Developer behind Notre Dame redevelopment trying to sell another downtown property e owner behind two high-profile downtown developments, including at the former site of the Notre Dame des Canadiens Church, appears to have gotten into financial trouble with the City of Worcester and wants to unload one of the properties. e proposed apartment building in the heart of Worcester's downtown CitySquare project area appears to be off the table, as the property has been re-listed for sale and the City of Worcester has filed a municipal lien on two parcels owned by the proposed developer of the property for unpaid property taxes. Foresight Capital, the Rhode Island-based property development company that owns 3 Eaton Place, had planned on constructing a seven-story building with 145 apartment units and commercial space designated for a grocery store and restaurant space. Now, the 3.91-acre lot has been re-listed for sale with an asking price of $5.25 million, according to a post on LoopNet, a real estate listing website. Foresight bought the property for $5 million in April 2022, according to City of Worcester records. e City has filed a municipal lien on the property with the Worcester District Registry of Deeds for unpaid financial obligations totalling $35,181. Documents submitted to the registry show Foresight Capital owes $33,819 in unpaid property taxes and $1,362 in other unpaid obligations to the City. A lien has also been filed for 5 Salem Square, the former site of the Notre Dame des Canadiens Church, which was demolished in 2018 and is also owned by the same developer. Foresight owes the City $106,252. On the Notre Dame property, Foresight has proposed building a 163-unit mixed-use building featuring 28,000-square-feet of commercial space. e company has not re-listed that property for sale. Amazon Best Seller! 508-757-3311 • www.sgllp.com Worcester Framingham Your Business is Our Top Priority We know business moves quickly today and your organization needs partners it can rely on. At S&G we have the knowledge, technical expertise and industry experience to get the job done. You'll always be our top priority! We'll be there to help with Value Growth Planning - strategic planning to grow revenue, increase profitability, and strengthen organizational structure to ensure long-term sustainability. Combine that with our "Awesome Service Guarantee" - our commitment to customer care and personal attention - and you'll see why S&G is the partner of choice for so many winning organizations. • Accounting & Tax Services • Business Consulting • Business Transition & Exit Planning • M&A Advisory • Financial Services • Retirement Planning For more information, or to set up your no obligation initial consultation, please contact us today. Co-authored by Terry Shepherd of Worcester's S&G LLP - Business Consultants and Certified Public Accountants Based on more than 45+ years experience working with business owners. Matt Britz, CEO of AffyImmune Therapeutics W

• Cover